After Pfizer’s return to price levels closer to its pre-COVID range, I personally believe the stock is undervalued relative to its current earnings profile and long-term potential. This view is also influenced by Pfizer’s recent acquisition of Metsera, which brings a pipeline of obesity and cardiometabolic candidates — including GLP-1 receptor agonists, an amylin analog, and other metabolic therapies.
Whether this pipeline ultimately succeeds is uncertain, but in my opinion, it meaningfully strengthens Pfizer’s long-term outlook.
This campaign is structured as a hedged, conservative covered-call income strategy, combining downside protection with steady premium generation.
Current Position
1. Long Shares: 700 shares @ $24.94
2. Protective Long Puts: 7 puts @ $19 strike (exp. 1/16/26), Cost: $35 total
Because PFE’s implied volatility is relatively low, these long-dated puts provide very inexpensive downside protection, defining maximum risk and allowing me to run covered calls with confidence. This is my preferred way to reduce tail risk on slower-moving stocks.
Covered Calls (Income)
I am selling near-term calls at the $25 strike and rolling as needed.
Call Activity So Far:
A. Initial Sell
• 7 contracts @ $0.11 → $77 total
• Expiration: 11/07/2025
B. Roll #1
• 7 contracts @ $0.15 → $105 total
• Expiration: 11/11/2025
C. Roll #2
• 7 contracts @ $0.15 → $105 total
• Expiration: 11/17/2025
Dividend Component:
Pfizer’s dividend provides a third income source that complements the weekly call premiums. With 700 shares, my next scheduled dividend payment is $310.89 on December 1st. this is nearly a 7% yield.
Dividends enhance this strategy by:
1. Reducing effective cost basis over time
2. Providing a reliable quarterly income
3. Making slower-moving stocks like PFE well-suited for hedged income trading
4. Smoothing returns even during flat price periods
This is one reason I favor PFE for long-term defensive income strategies.
These rolls follow my usual “roll out only” approach — extending time value without paying unnecessary extrinsic premium. This keeps weekly income stable while managing assignment risk.
Whether this pipeline ultimately succeeds is uncertain, but in my opinion, it meaningfully strengthens Pfizer’s long-term outlook.
This campaign is structured as a hedged, conservative covered-call income strategy, combining downside protection with steady premium generation.
Current Position
1. Long Shares: 700 shares @ $24.94
2. Protective Long Puts: 7 puts @ $19 strike (exp. 1/16/26), Cost: $35 total
Because PFE’s implied volatility is relatively low, these long-dated puts provide very inexpensive downside protection, defining maximum risk and allowing me to run covered calls with confidence. This is my preferred way to reduce tail risk on slower-moving stocks.
Covered Calls (Income)
I am selling near-term calls at the $25 strike and rolling as needed.
Call Activity So Far:
A. Initial Sell
• 7 contracts @ $0.11 → $77 total
• Expiration: 11/07/2025
B. Roll #1
• 7 contracts @ $0.15 → $105 total
• Expiration: 11/11/2025
C. Roll #2
• 7 contracts @ $0.15 → $105 total
• Expiration: 11/17/2025
Dividend Component:
Pfizer’s dividend provides a third income source that complements the weekly call premiums. With 700 shares, my next scheduled dividend payment is $310.89 on December 1st. this is nearly a 7% yield.
Dividends enhance this strategy by:
1. Reducing effective cost basis over time
2. Providing a reliable quarterly income
3. Making slower-moving stocks like PFE well-suited for hedged income trading
4. Smoothing returns even during flat price periods
This is one reason I favor PFE for long-term defensive income strategies.
These rolls follow my usual “roll out only” approach — extending time value without paying unnecessary extrinsic premium. This keeps weekly income stable while managing assignment risk.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.